CAT.one™ - Abuse Deterrent Formulations
Christopher Altomare
CEO @ Nova Analytic Labs | Leading Cannabis and PFAS Testing Provider
HORSHAM, Pa., Aug. 5, 2015 /PRNewswire/ -- DRUGSCAN© Pharmaceutical Services, a division of DRUGSCAN©, announced the introduction of CAT.one™ laboratory-based manipulation and extraction studies, designed to satisfy the US Food and Drug Administration's (FDA) requirements for abuse-deterrent opioid pharmaceutical products.
To address the epidemic rise in prescription opioid drug abuse, pharmaceutical companies have been developing opioid pain relievers that resist physical and chemical manipulation techniques used by drug abusers. In April 2015, the FDA issued final guidance on what studies pharmaceutical companies would need to conduct to demonstrate that their products deter common methods of abuse. The studies within the guidance are broken down into four categories. Category 1 is manipulation and extraction studies...